R97.21
Rising PSA following treatment for malignant neoplasm of prostate
Clinical Classification Guidelines
Medical Intelligence & Overview
A rising prostate-specific antigen (PSA) level after treatment for prostate cancer can be an important sign of a potential recurrence or persistence of the disease. This condition is identified by the ICD-10 code R97.21. Monitoring PSA levels is a common part of post-treatment follow-up for prostate cancer patients, helping healthcare providers evaluate the effectiveness of therapy and decide on further management strategies.
Causes & Symptoms
Clinical Causes: Recurrence of prostate cancer Persistent or residual cancer cells after initial treatment Other benign conditions affecting the prostate such as benign prostatic hyperplasia (though less common) Secondary prostate cancer spreading to other areas
Key Symptoms: Typically, there are no specific symptoms associated directly with rising PSA levels, which is why regular testing is important Possible symptoms if the cancer recurs or progresses may include: Difficulty urinating Blood in urine or semen Pelvic or lower back pain Unexplained weight loss Fatigue
Diagnostic & Treatment
Diagnosis Path: Detection of a rising PSA level involves a blood test that measures the amount of prostate-specific antigen in the bloodstream. Post-treatment PSA levels are usually very low or undetectable; a subsequent increase suggests possible recurrence. Healthcare professionals may recommend additional diagnostic procedures such as:
Treatment Protocols: Management of a rising PSA after prostate cancer treatment depends on various factors including the extent of disease, patient health, and prior treatments. Possible options include:
Clinical Advice & FAQs
Billing Guidance
Is R97.21 a billable ICD-10 code?
Yes, R97.21 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report R97.21?
Clinical documentation must specify the nature of Rising PSA following treatment for malignant neoplasm of prostate and any associated comorbidities for accurate reporting.
Cite this Clinical Reference